Form 4: SpringWorks Therapeutics Director Julie Hambleton Sells Shares
SEC Form 4 Filing
Director Julie Hambleton sold shares of SpringWorks Therapeutics (SWTX) on June 3, 2024, under a pre-arranged trading plan.
Summary
- On June 3, 2024, Julie Hambleton, a director of SpringWorks Therapeutics, sold a total of 4,648 shares of common stock.
- The sales were executed in multiple transactions at varying prices.
- The prices ranged from $39.02 to $42.17 per share.
- The sales were conducted under a pre-arranged trading plan (Rule 10b5-1) adopted on March 1, 2024.
- Following the reported transactions, Hambleton directly owns 4,095 shares of SpringWorks Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock sales by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding concerns about trading on inside information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| June 3, 2024 | Date of the stock sale transactions. |
| June 5, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.